AIDOT announced on the 13th that, in connection with its AI cervical cancer diagnostic system (Cerviray), it has completed domestic patent registration for an “automated cervical cancer diagnosis system.”

The solution includes criteria for classifying malignant atypical vascular patterns, and the patent was registered for this component.

The AI solution is currently seeing tangible progress toward expansion not only in Southeast Asia but also into the Russian market, and the company is also pursuing full-scale entry into North America through joint investment.

CEO Jeong Jae-hoon said, “As the effectiveness and business viability of Cerviray, our AI cervical cancer solution, have been verified and proven in the global market, we expect latecomers and copycat businesses to gradually emerge,” adding, “With this patent registration, we will strengthen differentiation from global competitors and expedite entry into key individual countries through global patent filings.”

Published: October 13, 2021 / Korea Economic TV